We read with interest the study by Navarro-Millàn and colleagues on the use of anakinra in severe COVID-19 patients with acute respiratory insufficiency and hyper-inflammation (1). The Authors tried to identify the clinical phenotype that is most likely to benefit from anakinra treatment, in order to maximize utility and not to expose patients to unnecessary risks related to immunosuppression.
Anakinra for COVID-19: how to interpret elevations in serum liver enzymes